William Raj Sellers, M.D.
Affiliations: | Novartis, Basel, Basel-Stadt, France | ||
| Dana-Farber Cancer Institute and Harvard Medical School, USA | |||
| Broad Institute - Cancer Program |
Area:
oncologyGoogle:
"William Sellers"Mean distance: 19.98 (cluster 51)
Children
Sign in to add trainee| Levi A. Garraway | grad student | Dana-Farber Cancer Institute and Harvard Medical School (Cell Biology Tree) | |
| Jordi Barretina | post-doc | Dana-Farber Cancer Institute | |
| Derek Yung-Ho Chiang | post-doc | Dana-Farber Cancer Institute (FlyTree) | |
| Laurens Moore van Tienen | post-doc | ||
| Rameen Beroukhim | post-doc | 2003-2006 | Dana-Farber Cancer Institute |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Greulich H, Chen TH, Feng W, et al. (2024) Correction: Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. Plos Medicine. 21: e1004470 |
| Vijay V, Karisani N, Shi L, et al. (2024) Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets. Biorxiv : the Preprint Server For Biology |
| Chang L, Jung NY, Atari A, et al. (2024) Author Correction: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics |
| Chang L, Jung NY, Atari A, et al. (2023) Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics |
| Tiedt R, King FJ, Stamm C, et al. (2023) Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports. 42: 112297 |
| Bondeson DP, Mullin-Bernstein Z, Oliver S, et al. (2022) Systematic profiling of conditional degron tag technologies for target validation studies. Nature Communications. 13: 5495 |
| Cantor SB, Sellers WR, Pathania S, et al. (2022) David Livingston (1941-2021). Molecular Cell. 82: 4-7 |
| Ito T, Young MJ, Li R, et al. (2021) Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nature Genetics |
| LaMarche MJ, Acker MG, Argintaru A, et al. (2020) Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry |
| Palmer AC, Plana D, Gao H, et al. (2020) A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts. Cancer Research |